Biomarkers Archives - ACR Meeting Abstracts

Abstract Number: 0044 • ACR Convergence 2026
Integrative Multi-Omic Profiling of Lupus Nephritis Reveals MicroRNA Master Regulators of Immune Pathogenesis and Class-Specific Biomarkers
Alexandria Shumway¹, Antonio Arias¹, Vimal Derebail¹, Shruti Saxena Beem¹, Valerie Gartner¹, Matthew Schaner¹, Caroline Poulton¹, Manish Saha¹, Susan Hogan¹, Keisha Gibson¹, John Charles Jennette¹, Ronald Falk¹, Praveen Sethupathy², Terrence Furey¹, Saira Sheikh¹ and Shehzad Sheikh¹ Affiliations: ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Cornell University College of Veterinary Medicine, Ithaca, NY
Background/Purpose: Lupus nephritis (LN) remains among the most severe organ manifestations of systemic lupus erythematosus (SLE), yet current clinical and pathological tools have limited capacity…
Abstract Number: 0195 • ACR Convergence 2026
Baseline serum angiopoietin-like 4 is associated with subsequent end-stage kidney disease in patients with MPA or GPA
Jang Woo Ha¹ and Sang-Won Lee² Affiliations: ¹Yonsei university college of medicine, Yongin-si,Gyeonggi-do, South Korea, ²Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: This study investigated the clinical utility of serum angiopoietin-like 4 (ANGPTL4) in assessing current vasculitis activity and predicting subsequent complications in patients with microscopic…
Abstract Number: 0369 • ACR Convergence 2026
Pharmacodynamic Biomarkers in Biologic-Naïve Participants With Active and Erosive Psoriatic Arthritis: Results Through Week 48 From the Phase 3 APEX Study
Carolina Bobadilla Mendez¹, Proton Rahman², Christopher Ritchlin³, Eric Wadman⁴, Alexa Kollmeier⁵, Karissa Lozenski⁶, Carolyn Cuff⁷, Matthew Loza⁴, Sheng Gao¹, Philip Mease⁸, Loqmane Seridi⁹ and Danielle Murphy¹⁰ Affiliations: ¹Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ²Faculty of Medicine, Division of Rheumatology, Memorial University of Newfoundland, St. Johns, NL, Canada, St. John's, NL, Canada, ³University of Rochester Medical Center, Rochester, NY, ⁴Johnson & Johnson, Spring House, PA, ⁵Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ⁶Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁷Johnson & Johnson, Cambridge, MA, ⁸Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁹Johnson & Johnson, Spring House, PA, USA, Clifron Park, NY, ¹⁰Johnson & Johnson, San Diego, CA
Background/Purpose: Guselkumab (GUS), a fully human monoclonal antibody that selectively inhibits IL-23 and binds CD64, is indicated for active PsA, moderate-to-severe plaque psoriasis, and moderately-to-severely…
Abstract Number: 0566 • ACR Convergence 2026
EMR1 (ADGRE1) As a Biomarker of IFN-gamma Activity for Evaluation and Monitoring of MAS / HLH
Michael Lam¹, Musaab Alhezam², Courtney LeSon³, Casey Rimland⁴, Seigo Okada⁵, Alexa Zambarano², Andrew Hsu², Emma Son², Yukai Huang² and Pui Lee⁵ Affiliations: ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, ³Boston Children's Hospital, Medford, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Boston Children's Hospital, Newton, MA
Background/Purpose: Interferon-γ is an essential cytokine for type I immunity against intracellular microbes. Excess production of IFN-γ is associated with cytokine storm syndromes including macrophage…
Abstract Number: 1024 • ACR Convergence 2026
Off-the-shelf Anti-CD19 CAR T-cell Therapy Efficacy Reveals Biomarker Candidates for Fatigue in SLE
Trever Greene¹, Shirley Pang², Jennifer Medlin³, Aikaterini Thanou⁴, Nimrah Bader⁴, Parastoo Fazeli⁵, Sheetal Desai⁶, Ben Parker⁷, Eleni Tholouli⁸, Shudan Wang⁹, Jonathan Graf¹⁰, Dag Leonard¹¹, Nora Singer¹², Matt Lunning³, Jeffrey Miller¹³, Natalie Shiff¹⁴, Carol Wong¹⁴, Beatrice Ferguson¹⁴, Bahram Valamehr¹⁵, Vaneet Sandhu¹⁴ and Lilly Wong¹⁴ Affiliations: ¹Fate Therapeutics, San Deigo, ²St. Jude Medical Center, Providence Medical Foundation, Fullerton, CA, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Oklahoma, Oklahoma City, OK, ⁵University of Minnesota, Minneapolis, MN, ⁶University of California Irvine School of Medicine, Irvine, CA, USA, Orange, CA, ⁷Kellgren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁸Manchester Royal Infirmary, Manchester, United Kingdom, ⁹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ¹⁰UCSF, San Francisco, CA, ¹¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ¹²The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ¹³University of Minnesota, Minneapolis, MN, USA, Minneapolis, MN, ¹⁴Fate Therapeutics, Inc., San Diego, CA, ¹⁵Fate Therapeutics, San Diego, CA
Background/Purpose: Fatigue is one of the most debilitating and simultaneously least understood symptoms of Systemic Lupus Erythematosus (SLE). Biomarkers associated with improvements in Functional Assessment…
Abstract Number: 1200 • ACR Convergence 2026
Serial CA 15-3 and KL-6, but not SP-D, correlate with pulmonary function, quantitative HRCT severity and disease activity in patients with systemic sclerosis-associated interstitial lung disease
Aashish Agrawal¹, Aditi Patankar², Khushboo Upadhyay³, Alpa Dherai⁴ and ROHINI SAMANT³ Affiliations: ¹P.D. Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India, ²P D Hinduja Hospital and Medical Research Centre, Mumbai, Mumbai, Maharashtra, India, ³P.D. Hinduja Hospital and Medical Research Centre, Mumbai, India, ⁴P.D. Hinduja Hospital and Medical Research Centre, Mumbau, India
Background/Purpose: Pulmonary function test (PFT) and high-resolution computed tomography (HRCT) are standard tools for diagnosis and monitoring of interstitial lung disease (ILD) in systemic sclerosis…
Abstract Number: 1336 • ACR Convergence 2026
Bridging the Gut-Joint Axis: Diagnostic and Prognostic Performance of Fecal Calprotectin in Axial Spondyloarthritis
Aysal Mahmood¹, Saourabh Rajesh Desai², Riya Shah³, Mariana Vanoye Tamez,⁴ and Syeda Sayeed⁵ Affiliations: ¹New York Medical College/Landmark Medical Center, Westwood, MA, ²Landmark Medical Center, Cumberland, RI, ³New York Medical College/ Landmark Medical Center, Cumberland, RI, ⁴Boston University Medical Center (BUMC), Boston, MA, ⁵NYMC/Landmark Medical Center, Woonsocket, RI
Background/Purpose: Subclinical intestinal inflammation is common in axial spondyloarthritis (axSpA) and may contribute to disease heterogeneity, treatment selection, and later development of inflammatory bowel disease (IBD).…
Abstract Number: 1462 • ACR Convergence 2026
Study Of Neuropeptides In Rheumatoid Arthritis And Their Role In The Inflammatory Response
Andres Perez Hurtado¹, Elena Grau García², Alba Maria Torrat Noves³, Daniel Ramos Castro⁴, Iago Alcántara Álvarez⁵, Belén Villanueva Mañes⁶, Miguel Simeó Vinaixa⁶, patricia anton Enguidanos⁶, Belen diaz Mora⁶ and Jose Andres Roman Ivorra⁷ Affiliations: ¹1.Rheumatology Department. HUIP La Fe; 2.Doctoral School. Catholic University of Valencia San Vicente Mártir, València, Comunidad Valenciana, Spain, ²HUP La Fe, Valencia, Spain, ³1.Rheumatology Department. HUP La Fe; 2.Doctoral School. Catholic University of Valencia San Vicente Mártir, Valencia, Spain, ⁴Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁵Rheumatology Department Hospital Universitari i Politècnic La Fe, València, Spain, ⁶Rheumatology Department. HUP La Fe, Valencia, Spain, ⁷Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease associated with persistent pain, disability and a significant impact on quality of life.In recent years, it…
Abstract Number: 1793 • ACR Convergence 2026
Salivary Flow as a Non-Invasive Biomarker of Periodontal Disease in Patients with Rheumatic Diseases
Natalia Guajardo-Jauregui¹, Morayma Rivera-Long¹, Valeria Mata-Riega², Paola Michelle Vega-Cobos¹, Nadia Danna Lopez-Rodriguez¹, Jesus Alberto Cardenas-de la Garza¹, Jorge Esquivel³, Dionicio Angel Galarza-Delgado¹ and Janett Carmen Riega Torres¹ Affiliations: ¹Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico, ²Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, ³Internal Medicine Department and Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González" de la Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, MONTERREY, Mexico
Background/Purpose: Oral manifestations are common in patients with rheumatic diseases and include xerostomia, periodontal disease, and dental impairment. Periodontal disease has been associated with increased…
Abstract Number: 1969 • ACR Convergence 2026
Proteomic Profiling Reveals Immune, Metabolic and Tissue Stress Pathways Associated with Articular Disease Burden in Systemic Sclerosis
Giulia Cruciani¹, Rebecca Ross², Marco Minerba³, Veronica Batani⁴, Letizia Pia Di Corcia⁵, Giacomo Cafaro¹, Carlo Perricone¹, Elena Bartoloni Bocci⁶ and Francesco Del Galdo³ Affiliations: ¹University of Perugia, Perugia, Italy, ²Medicine and Health, University of Leeds, Leeds, United Kingdom, ³University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom. 2.University of Modena and Reggio Emilia, Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, Modena, Italy, Leeds, United Kingdom, ⁵University of Campus Biomedico, Roma, ⁶Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
Background/Purpose: Articular involvement is a common feature in Systemic Sclerosis (SSc) and has been associated with greater disability, disease progression and interstitial lung disease (1-3).…
Abstract Number: 2022 • ACR Convergence 2026
Multi Omics Integration Reveals Treatment and Plaque Dependent Molecular Signatures in Biologic Naïve Rheumatoid Arthritis Patients Receiving csDMARDs, TNF Inhibitors or Baricitinib
Laura Muñoz-Barrera¹, Alexandra E Oppong², Rafaela Ortega-Castro³, Sagrario Corrales Díaz-Flores⁴, Jerusalem Calvo⁵, Concepción Aranda-Valera⁶, Maria Lourdes Ladehesa Pineda⁷, Junjie Peng⁸, Ismael Sánchez Pareja⁹, MºCarmen Ábalos-Aguilera¹⁰, Christian Merlo¹¹, Mº Ángeles Aguirre Zamorano¹², Pedro Seguí¹³, Tomás Cerdó¹⁴, Nuria Barbarroja¹⁵, Rocío González Conejero¹⁶, Constantino Martínez¹⁶, Carlos Perez-Sanchez¹⁷, George A Robinson¹⁸, Elizabeth C Jury¹⁹, Chary Lopez-Pedrera²⁰ and Alejandro Escudero Contreras²¹ Affiliations: ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²Centre for Rheumatology, Division of Medicine, University College London, London, UK, Centre for Rheumatology, Division of Medicine, University College London, London, UK, United Kingdom, ³Hospital Reina Sofía, Cordoba, Spain, ⁴IMIBIC, Córdoba, Spain, ⁵Hospital Reina Sofía, Hospital Reina Sofía, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, ⁷Reina Sofia Universitary Hospital, Cordoba, Andalucia, Spain, ⁸Centre for Adolescent Rheumatology versus Arthritis, Department of Medicine, University College London, London W1CE 6JF, UK, London, ⁹IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Andalucia, Spain, ¹⁰Reina Sofía University Hospital, Rheumatology Department, Córdoba, Andalucia, Spain, ¹¹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain., Cordoba, Spain, ¹²Reina Sofía University Hospital, Rheumatology Department, Cordoba, Andalucia, Spain, ¹³IMIBIC/Reina Sofia Hospital/University of Cordoba, Rheumatology, Córdoba, Spain., Córdoba, Spain, ¹⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, ¹⁵University of Cordoba, Cordoba, Andalucia, Spain, ¹⁶Servicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB Pascual Parrilla, Murcia, Spain, ¹⁷IMIBIC, Cordoba, Andalucia, Spain, ¹⁸Aging, Rheumatology & Regenerative Medicine, Division of Medicine, University College London, London, UK., London, United Kingdom, ¹⁹Centre for Rheumatology, Division of Medicine, University College London, London, UK, London, United Kingdom, ²⁰IMIBIC - Reina Sofia Hospital, Cordoba, Andalucia, Spain, ²¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain
Background/Purpose: To characterize molecular networks associated with therapeutic response in RA patients receiving csDMARDs, TNFi or Baricitinib, and to assess whether cardiovascular risk factors modify…
Abstract Number: 2176 • ACR Convergence 2026
Neutrophil-to-Lymphocyte Ratio Is Associated With Progression From VEDOSS to Definite Systemic Sclerosis
Francesco Bonomi¹, Cristiano Barbetta², Martina Iacubino³, Veronica De Silvestri⁴, Silvia Peretti⁵, Lorenzo Beretta⁶, Chiara Bellocchi⁷ and Silvia Bellando Randone⁸ Affiliations: ¹Azienda Ospedaliera Universitaria Careggi, Florence, Italy, ²Department of Experimental and Clinical Medicine, Division of Rheumatology, Florence, Italy, ³Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁴University Hospital Careggi, Florence, Italy, ⁵Department of Internal Medicine, Careggi University Hospital, Florence, Italy, ⁶Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ⁷4. Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy, ⁸Department of Experimental and Clinical Medicine, University of Florence, Rheumatology Division, Scleroderma Unit. AOU Careggi, Florence, Italy, Florence, Italy

Background/Purpose: Risk stratification in VEDOSS remains challenging, as only a proportion of patientsprogress to definite systemic sclerosis (SSc) during follow-up. Current predictors are mainlyclinical, serological…
Abstract Number: 2390 • ACR Convergence 2026
Clustering Profiles of Bioactive Lipids and Prediction of Clinical Response in Rheumatoid Arthritis
Kaitian Jin¹, Joshua Baker¹, Rocio Paz-Gonzalez², Misti L Paudel³, Joel Kremer⁴, Dimitrios Pappas⁵, Mona Alotaibi⁶ and Monica Guma⁷ Affiliations: ¹University of Pennsylvania, Philadelphia, PA, ²Medicine Department. University of California, San Diego, San Diego, CA, ³Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴The Corrona Research Foundation, Delray Beach, FL, ⁵CorEvitas, New York, NY, ⁶University of California, San Diego, San DIego, ⁷UCSD, La Jolla, CA
Background/Purpose: Disruptions in key energetic and inflammatory pathways, including altered lipid oxidation products, increased oxidative stress, and dysregulated lipid metabolism are associated with synovial inflammation…
Abstract Number: 2680 • ACR Convergence 2026
Predicting Immune-Related Inflammatory Arthritis in Patients with Cancer Receiving Immunotherapy Using Machine Learning
Harshita Raghavan¹, Shamey Kassim², Londyn Robinson², Pankti Reid³, Wooyoung Kim² and Namrata Singh⁴ Affiliations: ¹University of Washington, Seattle, ²University of Washington, Seattle, WA, ³University of Chicago Medical Center, Elmhurst, IL, ⁴University of Washington, Bellevue, WA
Background/Purpose: Immune checkpoint inhibitor (ICI)-associated inflammatory arthritis (IA) is an increasingly recognized rheumatic immune-related adverse event that can adversely affect both quality of life and…
Abstract Number: 2940 • ACR Convergence 2026
B-cell Counts and Inflammation Markers Predicting Prevalence and Severity of Cytokine-Release Syndrome in CAR T-Cell Therapy of Patients with Autoimmune Disease
Shirley Chan¹, Koray Tascilar², Andreas Wirsching², Soraya Kharboutli³, Fabian Mueller³, He Huang⁴, Jingjing Feng⁴, HUJI XU⁵, Ann-Christin Pecher⁶, Joerg Henes⁷, Ioanna Minopoulou⁸, David Simon⁹, Gerhard Krönke¹⁰, Denise Walther¹¹, Dimitrios Mougiakakos¹¹, Christina Duesing¹², Joerg Distler¹³, Isabell Haase¹⁴, Martin Krusche¹⁵, Tobias Krickau¹⁶, Markus Metzler¹⁶, Laura Bucci², Simon Voelkl³, Tobias Rothe¹⁷, Jule Bachl¹⁸, Andreas Mackensen¹⁹, Ricardo Grieshaber-Bouyer²⁰, Georg Schett²¹ and Melanie Hagen² Affiliations: ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong, ²Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 5 - Hematology and Oncology, (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Hematology Institute and Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Hangzhou, China (People's Republic), ⁵Shanghai Changzheng Hospital, Shanghai, China (People's Republic), ⁶University Hospital Tübingen, Tübingen, Germany, ⁷University Hospital Tuebingen, Tuebingen, Germany, ⁸Universitätsmedizin Charite Berlin, Berlin, Germany, ⁹Charité -Universitätsmedizin Berlin, Berlin, Germany, ¹⁰Charite - Universitaetsmedizin Berlin, Dept. of Rheumatology and Clinical Immunology, Berlin, Berlin, Germany, ¹¹Department of Hematology, Oncology, and Cell Therapy, Otto-von-Guericke University, Magdeburg, Germany, Magdeburg, Germany,Magdeburg Center for Cell and Immune Therapy (MAZI), Otto-von-Guericke University, Magdeburg, Germany, Magdeburg, Germany, Magdeburg, Germany, ¹²Department of Rheumatology and Hiller Research Center, University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ¹³Department of Rheumatology and Hiller Research Center, University Hospital Duesseldorf, Medical Faculty of Heinrich-Heine University, Duesseldorf, Germany, ¹⁴University Clinic Hamburg Eppendorf, Hamburg, Germany, ¹⁵UKE, Hamburg, Germany, ¹⁶Department of Pediatrics and Adolescent Medicine, FAU Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ¹⁷Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ¹⁸Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ¹⁹Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²⁰Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²¹Department of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Chimeric antigen receptor (CAR) T-cell therapy opens new possibilities for the treatment of refractory B-cell driven autoimmune diseases (AID) (1). Cytokine-Release Syndrome (CRS) and…

Abstracts tagged "Biomarkers"